NBTX Nanobiotix S.A.
Price Chart
Executive Summary
Nanobiotix announced FDA acceptance of a protocol amendment to its pivotal NANORAY-312 study for JNJ-1900 (NBTXR3) in head and neck cancer. The amendment eliminates the interim analysis and modifies the final analysis to require fewer events and occur sooner, potentially accelerating the registration pathway. No financial figures or approval decision were disclosed.
Actionable Insight
Monitor for timing of NANORAY-312 final analysis readout, which could act as a catalyst. The accelerated timeline may bring forward potential regulatory submissions and milestone payments, but no revenue is guaranteed until approval.
Key Facts
- FDA accepted protocol amendment for NANORAY-312 study of JNJ-1900 (NBTXR3) in head and neck cancer.
- Amendment eliminates planned interim analysis and modifies final analysis to be conducted sooner with fewer events.
- Nanobiotix believes this could accelerate and expand global registration pathway.
- Company is eligible for milestone payments from J&J, but no specific amounts or timing provided.
Financial Impact
No financial figures disclosed; milestone payments from J&J are contingent on future regulatory and development milestones.
Risk Factors
- Clinical trial results may not support regulatory approval.
- Milestone payments depend on achieving specific development and regulatory events, which may not occur as anticipated.
- Johnson & Johnson controls the trial timeline, and further changes could occur.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287230 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
14d ago
|
Press Release
| $40.50 $35.20 | ▼ −13.09% | ▼ −13.56% | $35.88 (−11.41%) |
|
May 22, 2026
18d ago
|
Press Release
| $40.80 $36.76 | ▼ −9.90% | ▼ −11.11% | $35.88 (−12.06%) |
|
May 21, 2026
19d ago
|
Press Release
| $40.18 $40.41 | ▼ −0.57% | ▲ +1.03% | $35.88 (+10.70%) |
|
May 21, 2026
19d ago
|
Press Release
| $40.18 $40.41 | ▼ −0.57% | ▲ +1.03% | $35.88 (+10.70%) |
|
May 21, 2026
19d ago
|
Press Release
| $40.18 $40.40 | ▼ −0.55% | ▲ +1.30% | $35.88 (+10.70%) |
|
May 20, 2026
20d ago
|
Press Release
| $40.18 $40.40 | ▼ −0.55% | ▲ +1.30% | $35.88 (+10.70%) |
|
May 18, 2026
22d ago
|
6-K
| $49.48 $40.80 | ▼ −17.54% | ▼ −19.16% | $35.88 (−27.49%) |
|
May 17, 2026
23d ago
|
Press Release
| $49.48 $40.80 | ▼ −17.54% | ▼ −19.16% | $35.88 (−27.49%) |
|
May 4, 2026
5w ago
|
Press Release
| $34.77 $48.24 | ▲ +38.74% | ▲ +36.76% | $35.88 (+3.19%) |
|
Apr 20, 2026
7w ago
|
6-K
| $31.91 $33.11 | ▲ +3.76% | ▲ +2.85% | $35.88 (+12.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access